Effect of coadministered HIV-protease inhibitors on tacrolimus and sirolimus blood concentrations in a kidney transplant recipients

Fundamental and Clinical Pharmacology

Volumn 23, Issue 4, 2009, Pages 423-425

  Barau, Caroline ^a   Blouin, P ^a   Creput, Caroline ^a   Taburet, A M ^a   Durrbach, Antoine ^a,b   Furlan, Valérie ^a  

^a BICÊTRE HOSPITAL   (France)

^b INSERM   (France)

Author keywords

Fosamprenavir; Interaction; Ritonavir; Sirolimus; Tacrolimus

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; BASILIXIMAB; CREATININE; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; GLYCOPROTEIN P INHIBITOR; LAMIVUDINE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITONAVIR; TACROLIMUS; ZIDOVUDINE;

ADULT; ARTICLE; CASE REPORT; CD4+ T LYMPHOCYTE; CELL COUNT; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DIGESTIVE SYSTEM FUNCTION DISORDER; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG HALF LIFE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; ENZYME ASSAY; FOLLOW UP; GLOMERULOPATHY; GRAFT RECIPIENT; GRAFT REJECTION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOSUPPRESSIVE TREATMENT; KAPOSI SARCOMA; KIDNEY FAILURE; KIDNEY GRAFT; MAINTENANCE THERAPY; MALE; NEPHROTOXICITY; NEUROTOXICITY; PRIORITY JOURNAL; SINGLE DRUG DOSE;

DRUG INTERACTIONS; HALF-LIFE; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; SARCOMA, KAPOSI; SIROLIMUS; TACROLIMUS;

EID: 68749121062     PISSN: 07673981     EISSN: 14728206     Source Type: Journal    
DOI: 10.1111/j.1472-8206.2009.00706.x     Document Type: Article

References (14)

1. Kuo P.C., Stock P.G. Transplantation in the HIV+patient. Am. J. Transplant. (2001) 1 13 17.
2. Roland M.E., Stock P.G. Review of solid-organ transplantation in HIV-infected patients. Transplantation (2003) 75 425 429.
3. Kumar M.S., Sierka D.R., Damask A.M. et al. Safety and success of kidney transplantation and concomitant immunosuppression in HIV-positive patients. Kidney Int. (2005) 67 1622 1629.
4. Izzedine H., Launay-Vacher V., Baumelou A., Deray G. Antiretroviral and immunosuppressive drug-drug interactions: an update. Kidney Int. (2004) 66 532 541.
5. Sheikh A.M., Wolk D.C., Lebovics E. et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduces tacrolimus metabolism and increases blood levels. Transplantation (1999) 68 307 309.
6. Jain A.K.B., Ventakataramana R., Shapiro R. et al. Interaction between tacrolimus and antiretroviral agents in human immunodeficiency virus-positive liver and kidney transplantation patients. Transplant. Proc. (2002) 34 1540 1541.
7. Jain A.K.B., Venkataramanam R., Fridell J.A. et al. Nelfinavir, a protease inhibitor, increases sirolimus levels in a liver transplantation patient: a case report. Liver Transpl. (2002) 8 838 840.
8. Furlan V., Taburet A.M. Drug interactions with antiretroviral agents. Therapie (2001) 56 267 271.
9. Dasgupta A., Okhuysen P.C. Pharmacokinetics and other drug interactions in patients with AIDS. Drug Monit. (2001) 23 471 605.
10. Frasseto L.A., Browne M., Cheng A. et al. Immunosuppressant pharmacokinetics and dosing modifications in HIV-1 infected liver and kidney transplant recipients. Am. J. Transplant. (2007) 7 2816 2820.
11. Granfors M.T., Wang J.S., Kajosaari L.I. et al. Differential inhibition of cytochrome P450 3A4, 3A5 and 3A7 by five human immunodeficiency virus (HIV) protease inhibitors in vitro. Basic Clin. Pharmacol. Toxicol. (2006) 98 79 85.
12. Sattler M., Guenguerich F.P., Yun C.H. et al. Cytochrome P450 3A enzymes are responsible for biotransformation of FK506 and rapamycin in man and rat. Drug Metab. Dispos. (1992) 20 753 761.
13. Lemajieu W.P., Maes B.D., Verbeke K., Vanrenterghem Y. CYP3A4 and P-glycoprotein activity in healthy controls and transplant patients on cyclosporine vs tacrolimus vs sirolimus. Am. J. Transplant. (2004) 4 1514 1522.
14. Pogamy K., Van Valkengoed I.G., Prins Jm. et al. Effects of active treatment discontinuation in patients with a CD4+ T-cell nadir greater than 350 cells/mm3: 48-week treatment interruption in early starters Netherlands Study (TRIESTAN). J. Acquir. Immune Defic. Syndr. (2007) 44 395 400.